Literature DB >> 508687

Xenon arc panretinal photocoagulation for central retinal vein occlusion: a randomised prospective study.

D R May, M L Klein, G A Peyman, M Raichand.   

Abstract

Thirty-three patients with central vein occlusion were evaluated for the effects of scatter xenon arc panretinal photocoagulation. Thirty-four eyes (2 eyes of 1 patient) were randomly divided into a treatment (15 eyes) and a nontreatment group (19 eyes). The average follow-up per eye has been 29 months. The visual prognosis was not significantly better in either group. There was no difference in the development of fundus neovascularisation between groups. None of the patients in the treated group developed rubeosis or neovascular glaucoma. Two patients in the nontreatment group initially had rubeosis and 3 developed it after entry. All 5 involved eyes developed neovascular glaucoma. A significantly greater amount of central retinal capillary drop-out was present in the untreated eyes that developed rubeosis than those untreated eyes which did not. The eyes in the treated group had a similar range of capillary drop-out area, but none of these eyes developed rubeosis or neovascular glaucoma. Panretinal photocoagulation prevented the development of rubeosis and neovascular glaucoma in susceptible eyes.

Entities:  

Mesh:

Year:  1979        PMID: 508687      PMCID: PMC1043608          DOI: 10.1136/bjo.63.11.725

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  25 in total

1.  The causes and therapy of thrombosis of the retinal veins.

Authors:  J van LOON
Journal:  Ophthalmologica       Date:  1961-06       Impact factor: 3.250

2.  Experience of treating retinal venous occlusion with anticoagulant and antisclerosis therapy.

Authors:  S VANNAS; H ORMA
Journal:  AMA Arch Ophthalmol       Date:  1957-12

3.  A survey of the pathogenesis of retinal venous occlusion, emphasis upon choice of therapy and an analysis of the therapeutic results in fifty-three patients.

Authors:  B A KLIEN; J H OLWIN
Journal:  AMA Arch Ophthalmol       Date:  1956-08

4.  Central retinal vein thrombosis and hemorrhagic glaucoma.

Authors:  P BRAENDSTRUP
Journal:  Acta Ophthalmol Suppl       Date:  1950

5.  Argon laser photocoagulation in the treatment of retinal vein occlusions.

Authors:  H C Zweng; R C Fahrenbruch; H L Little
Journal:  Mod Probl Ophthalmol       Date:  1974

6.  Retinal branch vein occlusion. Treatment by photocoagulation.

Authors:  G W Cleasby; D L Hall; W E Fung; R G Webster
Journal:  Mod Probl Ophthalmol       Date:  1974

7.  Argon laser slitlamp photocoagulation. Indications and results.

Authors:  J François; E Cambie; J J De Laey
Journal:  Ophthalmologica       Date:  1974       Impact factor: 3.250

8.  A prospective study of xenon arc photocoagulation for central retinal vein occlusion.

Authors:  D R May; M L Klein; G A Peyman
Journal:  Br J Ophthalmol       Date:  1976-12       Impact factor: 4.638

9.  Ocular hypotony following retinal vein occlusion.

Authors:  S S Hayreh; W March; C D Phelps
Journal:  Arch Ophthalmol       Date:  1978-05

10.  Panretinal photocoagulation in central retinal vein occlusion: A randomised controlled clinical study.

Authors:  L Laatikainen; E M Kohner; D Khoury; R K Blach
Journal:  Br J Ophthalmol       Date:  1977-12       Impact factor: 4.638

View more
  7 in total

1.  Argon laser panretinal photocoagulation in ischemic central retinal vein occlusion. A 10-year prospective study.

Authors:  S S Hayreh; M R Klugman; P Podhajsky; G E Servais; E S Perkins
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1990       Impact factor: 3.117

2.  Central Vein Occlusion Study: photographic protocol and early natural history.

Authors:  J G Clarkson
Journal:  Trans Am Ophthalmol Soc       Date:  1994

3.  Panretinal cryotherapy in neovascular disease.

Authors:  S A Vernon; H Cheng
Journal:  Br J Ophthalmol       Date:  1988-06       Impact factor: 4.638

4.  Predictors of Neovascular Glaucoma in Central Retinal Vein Occlusion.

Authors:  Andrew J Rong; Swarup S Swaminathan; Elizabeth A Vanner; Richard K Parrish
Journal:  Am J Ophthalmol       Date:  2019-03-09       Impact factor: 5.258

5.  Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.

Authors:  Philip Hykin; A Toby Prevost; Sobha Sivaprasad; Joana C Vasconcelos; Caroline Murphy; Joanna Kelly; Jayashree Ramu; Abualbishr Alshreef; Laura Flight; Rebekah Pennington; Barry Hounsome; Ellen Lever; Andrew Metry; Edith Poku; Yit Yang; Simon P Harding; Andrew Lotery; Usha Chakravarthy; John Brazier
Journal:  Health Technol Assess       Date:  2021-06       Impact factor: 4.014

6.  A randomised prospective study on treatment of central retinal vein occlusion by isovolaemic haemodilution and photocoagulation.

Authors:  L L Hansen; P Danisevskis; H R Arntz; G Hövener; M Wiederholt
Journal:  Br J Ophthalmol       Date:  1985-02       Impact factor: 4.638

Review 7.  Efficacy and safety of widely used treatments for macular oedema secondary to retinal vein occlusion: a systematic review.

Authors:  Julie Glanville; Jacoby Patterson; Rachael McCool; Alberto Ferreira; Kerry Gairy; Ian Pearce
Journal:  BMC Ophthalmol       Date:  2014-01-21       Impact factor: 2.209

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.